Some laws in the United States define cannabis-impaired driving criteria using various per se language that uses specific concentrations of various cannabinoid compounds to establish driving-under-the-influence (DUI). We hypothesize that there will be decedents whose postmortem toxicology profiles would be considered indicative of an acute cannabinoid intoxication under varying DUI per se laws, despite having survived longer than the expected duration of cannabinoid impairment effects. This study examined decedents in whom quantified cannabis metabolites were detected in Connecticut medical examiner autopsy samples, in which the medically-confined survival interval was longer (4–12 and > 12 h) than the expected duration of cannabinoid impairment effects. Several of the 15 decedents, despite being intubated and/or comatose during the medically-confined period of abstinence, would have exceeded DUI per se limits based upon their toxicology results. The use of drug concentrations alone to equate to an acute cannabis intoxication may result in inappropriate arrest, prosecution, and civil liability.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
SAMHSA. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health. Department of Health and Human Services USA; 2015.
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–60.
Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction. 2009;104:2041–8.
Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149–56.
Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989;37:273–7.
Kelly P, Jones R. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16:228–35.
Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60:631–43.
Holland MG, Schwope DM, Stoppacher R, Gillen SB, Huestis MA. Postmortem redistribution of Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Sci Int. 2011;212:247–51.
Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107:1277.
Huestis MA. Cannabis-impaired driving: a public health and safety concern. Clin Chem. 2015;61:1223–5.
Turnbull D, Hodge JG. Driving under the influence of marijuana laws and the public's health. J Law Med Ethics. 2017;45:280–3.
Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013;59:519–26.
Armentano P. Should per se limits be imposed for cannabis? Equating cannabinoid blood concentrations with actual driver impairment: practical limitations and concerns. HJSR. 2013:45–55.
Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491–3.
Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996;34:446–52.
Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34:352–63.
Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retrovir. 1997;13:305–15.
Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep. 1984;68:1427–31.
Drummer OH. Postmortem toxicology of drugs of abuse. Forensic Sci Int. 2004;142:101–13.
Lemos NP, Ingle EA. Cannabinoids in postmortem toxicology. J Anal Toxicol. 2011;35:394–401.
Olson KN, Luckenbill K, Thompson J, Middleton O, Geiselhart R, Mills KM, et al. Postmortem redistribution of fentanyl in blood. Am J Clin Pathol. 2010;133:447–53.
Bosker WM, Karschner EL, Lee D, Goodwin RS, Hirvonen J, Innis RB, et al. Psychomotor function in chronic daily Cannabis smokers during sustained abstinence. PLoS One. 2013;8:e53127.
Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. Clin Chem. 2016;62:367–77.
Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16:276–82.
Andrews R, Murphy KG, Nahar L, Paterson S. Cannabinoid concentrations detected in fatal road traffic collision victims compared with a population of other postmortem cases. Clin Chem. 2015;61:1256–64.
Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev. 2008;40:926–34.
Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18:185–93.
Laumon B, Gadegbeku B, Martin JL, Biecheler MB, Group SAM. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005;331:1371.
Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013;60:254–67.
Conflict of interest
About this article
Cite this article
Schwerdt, M.K., Gill, J.R. The pitfalls of per se thresholds in accurately identifying acute cannabis intoxication at autopsy. Forensic Sci Med Pathol 14, 497–502 (2018). https://doi.org/10.1007/s12024-018-0019-2
- Forensic pathology
- Driving under the influence laws